The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1420
Kcentra: A 4-Factor Prothrombin Complex Concentrate for Reversal of Warfarin Anticoagulation
The full article is available to subscribers Subscriber Login   

The FDA has approved use of Kcentra (CSL Behring), a human-derived 4-factor prothrombin complex concentrate (PCC), for urgent reversal of warfarin anticoagulation in adults with acute major bleeding. It is the only 4-factor PCC available in the US.

PROTHROMBIN COMPLEX CONCENTRATES — The vitamin K-dependent coagulation factors are II, VII, IX and X. The composition of PCC products is variable. Three-factor PCC products include clotting factors II, IX and X, but contain little or no factor VII. Four-factor PCCs, which have been available in Europe and Canada for many years, include significant amounts of factor VII.1

REVERSING WARFARIN — Warfarin-related bleeding can be catastrophic, but it is reversible.2 Vitamin K can take more than 24 hours to fully restore vitamin K-dependent coagulation factors. Fresh-frozen ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Kcentra: A 4-Factor Prothrombin Complex Concentrate for Reversal of Warfarin Anticoagulation
Article code: 1420a
 Electronic, downloadable article - $35
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian